High Affinity Fluorescent Probe for Proteinase-Activated Receptor 2 (PAR2).
Journal
ACS medicinal chemistry letters
ISSN: 1948-5875
Titre abrégé: ACS Med Chem Lett
Pays: United States
ID NLM: 101521073
Informations de publication
Date de publication:
11 Jul 2019
11 Jul 2019
Historique:
received:
07
03
2019
accepted:
06
06
2019
entrez:
18
7
2019
pubmed:
18
7
2019
medline:
18
7
2019
Statut:
epublish
Résumé
PAR2 is a proteolytically activated G protein-coupled receptor (GPCR) that is implicated in various cancers and inflammatory diseases. Ligands with low nanomolar affinity for PAR2 have been developed, but there is a paucity of research on the development of PAR2-targeting imaging probes. Here, we report the development of seven novel PAR2-targeting compounds. Four of these compounds are highly potent and selective PAR2-targeting peptides (EC
Identifiants
pubmed: 31312406
doi: 10.1021/acsmedchemlett.9b00094
pmc: PMC6627725
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1045-1050Déclaration de conflit d'intérêts
The authors declare no competing financial interest.
Références
Nature. 1999 Mar 11;398(6723):156-60
pubmed: 10086357
J Pharmacol Exp Ther. 1999 Aug;290(2):753-60
pubmed: 10411588
Arch Biochem Biophys. 2001 Feb 15;386(2):195-204
pubmed: 11368342
Am J Pathol. 2002 Nov;161(5):1903-15
pubmed: 12414536
J Clin Invest. 2003 Jan;111(1):35-41
pubmed: 12511586
Cancer. 2003 Feb 1;97(3):703-13
pubmed: 12548614
J Pharmacol Exp Ther. 2004 Jun;309(3):1124-31
pubmed: 14976230
Mol Cancer Res. 2004 Jul;2(7):395-402
pubmed: 15280447
Br J Pharmacol. 2005 May;145(2):255-63
pubmed: 15765104
Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8363-8
pubmed: 15919826
Hum Pathol. 2005 Jun;36(6):676-85
pubmed: 16021575
J Surg Oncol. 2006 Feb 1;93(2):139-44
pubmed: 16425301
Am J Pathol. 2006 Jul;169(1):268-78
pubmed: 16816379
Arterioscler Thromb Vasc Biol. 2007 Jun;27(6):1456-62
pubmed: 17363687
Prostate. 2007 May 15;67(7):743-56
pubmed: 17373694
Bioorg Med Chem Lett. 2007 Oct 15;17(20):5552-7
pubmed: 17765542
J Biol Chem. 2008 May 2;283(18):12293-304
pubmed: 18308730
Gut. 2008 Sep;57(9):1222-9
pubmed: 18460552
J Pharmacol Exp Ther. 2008 Aug;326(2):453-62
pubmed: 18477767
Oncogene. 2009 Aug 27;28(34):3047-57
pubmed: 19543320
Arterioscler Thromb Vasc Biol. 2010 Nov;30(11):2136-42
pubmed: 20724699
J Korean Med Sci. 2010 Sep;25(9):1330-5
pubmed: 20808677
Am J Physiol Cell Physiol. 2011 Jan;300(1):C113-23
pubmed: 21068362
Pharmacol Ther. 2011 Jun;130(3):248-82
pubmed: 21277892
J Med Chem. 2011 Mar 10;54(5):1308-13
pubmed: 21294569
FASEB J. 2012 Jul;26(7):2877-87
pubmed: 22467762
Bioconjug Chem. 2012 Oct 17;23(10):2098-104
pubmed: 22994402
Mol Cell Proteomics. 2014 Feb;13(2):397-406
pubmed: 24309898
ACS Med Chem Lett. 2015 Nov 30;7(1):105-10
pubmed: 26819675
ACS Chem Biol. 2017 May 19;12(5):1217-1226
pubmed: 28169521
Hum Pathol. 2017 Jun;64:156-163
pubmed: 28438620
Eur J Biochem. 1995 Aug 15;232(1):84-9
pubmed: 7556175
Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9208-12
pubmed: 7937743
Can J Physiol Pharmacol. 1995 Aug;73(8):1203-7
pubmed: 8564891
Biochem J. 1996 Mar 15;314 ( Pt 3):1009-16
pubmed: 8615752
J Biol Chem. 1997 Feb 14;272(7):4043-9
pubmed: 9020112
Can J Physiol Pharmacol. 1997 Jul;75(7):832-41
pubmed: 9315351
J Pharmacol Exp Ther. 1999 Feb;288(2):671-8
pubmed: 9918574